[NEW YORK] – Morgan & Morgan has filed a lawsuit against Novo Nordisk and Eli Lilly and Company, the manufacturers of diabetes and weight loss drugs Ozempic® and Mounjaro™, alleging that the companies failed to warn of the risk of significant injuries caused by the drugs.
Plaintiff Jaclyn Bjorklund, of DeRidder, LA, was prescribed both Ozempic® and Mounjaro™ and took the medications for a total of about a year and a half before stopping this summer. Ms. Bjorklund alleges the medications caused her severe gastrointestinal issues including stomach paralysis, also known as gastroparesis, which led to her being hospitalized several times for vomiting and stomach pain. She also alleges that some of her teeth fell out due to excessive vomiting. In addition to filing Ms. Bjorklund’s lawsuit, Morgan & Morgan has been retained by more than 500 clients from 45 states to investigate their claims and hold the pharmaceutical companies that produce these types of drugs accountable for the drugs’ alleged side-effects.
Ms. Bjorklund and other clients who have retained Morgan & Morgan allege that patients taking Ozempic® and/or Mounjaro™ are at a higher risk for severe gastrointestinal problems, including gastroparesis. If the muscles that propel food through the digestive tract are paralyzed, it can cause nausea, vomiting, abdominal pain and bloating, as well as malnutrition and severe dehydration. Morgan & Morgan is additionally investigating claims of injuries allegedly caused by weight loss drugs including Wegovy, Rybelsus and Saxenda.
“Ms. Bjorklund put her trust in Novo Nordisk and Eli Lilly and Company, and we believe that as a result she has gone through a hell that no one should have to endure,” said Morgan & Morgan partner Paul Pennock. “Ms. Bjorklund, as well as the over 500 clients across 45 states whose claims we continue to investigate, have suffered ongoing gastrointestinal problems that in many cases are severe, debilitating and disabling. Some of the injuries may be permanent. Filing this lawsuit is the first step in holding these companies accountable for their alleged failure to warn patients about the significant risks posed by these drugs.”
Ozempic® and Mounjaro™ are both injectable drugs used to treat type II diabetes by acting on hormone receptors to reduce blood sugar levels. These drugs have also been commonly used off-label for weight loss.
The complaint for the case can be viewed here. A recording of the Zoom press conference conducted earlier today with Morgan & Morgan attorneys Paul Pennock, Jonathan Sedgh and Rene Rocha can be accessed here.